Crossmark

Low-dose nivolumab plus induction chemotherapy for locally advanced or unresectable head and neck cancer is associated with high response rates and conversion to definitive therapy

Crossref DOI link: https://doi.org/10.1038/s41598-025-19197-y

Published Online: 2025-10-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Georgy, Josh Thomas

Regi, Soumya Susan

Georgy, Rosh Varghese

Sasidharan, Balu Krishna

Joel, Anjana

Philip, Deepa Susan Joy

John, Ajoy Oommen

Thumaty, Divya Bala

Marimuthu, Praveen Kumar

Jambunathan, Prashant

Harikrishna, Kovilapu

Thomas, Zachariah

Rani, N. Jansi

Tirkey, Amit Jiwan

Thomas, Meera

Isiah, Rajesh

Singh, Ashish
License Information

Text and Data Mining valid from 2025-10-08

Version of Record valid from 2025-10-08
More Information

Article History

Received: 6 April 2025

Accepted: 5 September 2025

First Online: 8 October 2025

Declarations

:

: The authors declare no competing interests.

: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study protocol was approved by the Institutional Review Board (Institutional Ethics Committee) of Christian Medical College (CMC) Vellore [IRB no. 15358 dated 19.4.2023].

Document is current

Any future updates will be listed below